Conatus Pharmaceuticals Inc (CNAT)

4.99
0.04 0.80
NASDAQ : Health Care
Prev Close 5.03
Open 5.02
Day Low/High 4.88 / 5.20
52 Wk Low/High 1.40 / 7.12
Volume 331.22K
Avg Volume 1.09M
Exchange NASDAQ
Shares Outstanding 26.17M
Market Cap 126.14M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Market Sees Rise in Performance Anxiety

Market Sees Rise in Performance Anxiety

I've got my eye on steel and biotechnology names to put cash to work.

Traders Are Cleaning Out Their Portfolios: Rev Shark's Best Blog

Traders Are Cleaning Out Their Portfolios: Rev Shark's Best Blog

Rev Shark steps in for Jim Cramer this week.

Traders Are Cleaning Out Their Portfolios

Traders Are Cleaning Out Their Portfolios

Thin trading is impeding momentum, but here are 4 stocks on my radar.

Rev's Forum: Pension Fund Rebalancing Acts Could Impact 2016's Finish

Rev's Forum: Pension Fund Rebalancing Acts Could Impact 2016's Finish

Will pension funds sell stocks after their run higher in order to maintain the same allocation levels to bonds and equities?

Santa Claus Rally: Ya Gotta Believe

Santa Claus Rally: Ya Gotta Believe

Today's action is a classic example.

Futures Point North; Asia Mixed, Despite European Attacks

Futures Point North; Asia Mixed, Despite European Attacks

Markets look set to continue their election rally as violence casts a pall over Europe.

Here's Why Conatus Pharmaceuticals (CNAT) Stock Is Soaring Today

Here's Why Conatus Pharmaceuticals (CNAT) Stock Is Soaring Today

Conatus Pharmaceuticals (CNAT) stock was boosted on Tuesday after Allergan (AGN) agreed to buy Tobira Therapeutics (TBRA) at a 500% premium.

These Biotech Names Are on My Radar

These Biotech Names Are on My Radar

But I'm expecting that things will slow into the Fed news.

Conatus Pharmaceuticals (CNAT) Stock Surges, Liver Drug Could Treat Zika

Conatus Pharmaceuticals (CNAT) Stock Surges, Liver Drug Could Treat Zika

Conatus Pharmaceuticals' (CNAT) patented liver drug emricasan has been identified as a promising treatment for the Zika virus.

Exalenz Bioscience Announces Collaboration with Conatus Pharmaceuticals to Use BreathID® to Monitor Patients with Cirrhosis Associated with NASH

Exalenz Bioscience Announces Collaboration with Conatus Pharmaceuticals to Use BreathID® to Monitor Patients with Cirrhosis Associated with NASH

Company's non-invasive BreathID® System to be used to quantitate liver function in Conatus Phase IIb clinical trial of emricasan; Currently no approved non-invasive diagnostic tests exist to diagnose or monitor NASH which affects 2-5% of the US population

Conatus Pharmaceuticals Reports First Quarter 2016 Financial Results And Program Updates

Conatus Pharmaceuticals Reports First Quarter 2016 Financial Results And Program Updates

Conference Call and Webcast Presentation at 8:00 a.m. ET Today